The alagille syndrome treatment market size is projected to expand from USD 0.88 billion in 2025 and USD 0.95 billion in 2026 to USD 1.41 billion by 2031, registering a CAGR of 8.22% between 2026 to 2031. This report is Segmented by Treatment Modality, Drug Class (IBAT Inhibitors, UDCA, Bile Acid Sequestrants, Rifampicin, Vitamins, Other), Route of Administration (Oral, Injectable, Other), Patient Age Group (Infants, Children 1-11 Yrs, Adolescents, Adults), End User, and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).
Surgical intervention is forecast to grow at a CAGR of 9.15% from 2026 to 2031, reflecting more patients reaching transplantation thresholds as treated cohorts age. The supplied research states that 20-30% of patients ultimately require liver transplantation for conditions including intractable pruritus and progressive liver dysfunction. Supportive care, transplant preparation, and post-transplant management continue to address advanced disease needs and reinforce the role of multidisciplinary centers.
Ileal bile acid transporter inhibitors accounted for 38.55% of the Alagille syndrome treatment market size within the drug class and active ingredient segment in 2025. This position reflected orphan pricing, recent approvals, and the lack of another high-value targeted agent described in the supplied research. Maralixibat and odevixibat remained the principal medicines in this class, with differences in approved age range, formulation, and distribution arrangements influencing prescribing decisions.
Maralixibat is forecast to grow at a CAGR of 10.80% from 2026 to 2031. Its growth is linked to approvals across more than 40 countries, the June 2025 tablet launch, and completed enrollment of the Phase 3 EXPAND study in March 2026. Topline data are expected in the fourth quarter of 2026, and the study could support a label extension to biliary atresia, while supportive therapies remain relevant where IBAT inhibitors are not reimbursed.
Canada expanded its treatment setting during 2025 after odevixibat approval and the conclusion of maralixibat reimbursement negotiations, while Mexico’s less developed rare-disease insurance framework limited near-term use outside urban tertiary centers. Europe is the second-largest geography in the supplied research, with Germany, the United Kingdom, and France forming the main country markets. The 2025 European authorization of LIVMARLI tablets and the 2024 conditional approval of odevixibat created a two-IBAT-inhibitor setting, although national assessment processes differ across countries and can create uneven access.
Asia-Pacific is forecast to grow at a 9.58% CAGR from 2026 to 2031, the fastest regional rate in the supplied estimates. The region is a key growth area for the Alagille syndrome treatment market. Japan approved maralixibat in March 2025, and China expanded its label to patients aged 3 months and older in May 2024. CANbridge and Baheal Medical formed a partnership in August 2025 covering mainland China, Hong Kong, and Macau, while Australia’s PBAC completed an odevixibat review in March 2026.
Global Alagille Syndrome Treatment Market Trends and Insights
Sequential IBAT Inhibitor Label Expansions Add New Patient Cohorts With Each Regulatory Cycle
The expansion of maralixibat and odevixibat approvals to younger patient groups remained a direct demand driver for the Alagille syndrome treatment market. The U.S. Food and Drug Administration approved a Livmarli tablet formulation in April 2025 for patients weighing at least 25 kg, allowing eligible adolescents to transition from a liquid medicine to a once-daily tablet. In Europe, odevixibat received conditional approval in September 2024 for patients aged 6 months and older, covering a younger group than the U.S. indication described in the supplied research.PRO-Based Endpoint Validation Transforms Payer Evidence Requirements for Cholestatic Pruritus Treatment
Cholestatic pruritus has shifted from a symptom managed in routine care to an endpoint that clinical studies can measure. ItchRO(Obs) and PRUCISION are observer-reported tools used to record itch-related effects in children, and the Phase 3 ASSERT trial reported a mean pruritus score improvement of -0.88 with odevixibat, with p=0.0012. This evidence supported the regulatory approvals described in the source material and gave payers a clearer basis for assessing clinical benefit. The MERGE study recorded a clinically meaningful ItchRO(Obs) change from baseline of -2.14 at year 7 for maralixibat, strengthening reimbursement evidence with long-term patient-reported outcomes.Ultra-Rare Patient Numbers Cap Volume Growth Independent Of Pricing And Geography
Even with improved diagnosis, the globally diagnosed patient population remains in the low thousands, creating a structural limit on volume growth in the Alagille syndrome treatment market. The GALA cohort included 952 patients and reported a median serum bile acid level of 147 μmol/L at onset, indicating that some patients reach specialist care only after substantial cholestasis has developed. The supplied research also states that 5-7% of JAG1 pathogenic variants are structural deletions that require chromosomal microarray analysis, which is not available in all community settings.Other drivers and restraints analyzed in the detailed report include:
- NGS-Driven Diagnostic Expansion Reveals A Larger, Previously Invisible Patient Population
- Growing Pediatric Liver-Center Networks Directly Determine Treatment Uptake In Each Market
- High Therapy Costs And Multi-Layer Reimbursement Processes Delay Patient Access In Key Markets
Segment Analysis
Pharmacological therapy held 61.24% of the Alagille syndrome treatment market share within the treatment modality segment in 2025. Targeted IBAT inhibitors and established supportive medicines supported this leading position. Ursodeoxycholic acid, bile acid sequestrants, antipruritic agents, and fat-soluble vitamin formulations remained part of routine care, while IBAT inhibitors added a higher-value targeted option for eligible patients with cholestatic pruritus.Surgical intervention is forecast to grow at a CAGR of 9.15% from 2026 to 2031, reflecting more patients reaching transplantation thresholds as treated cohorts age. The supplied research states that 20-30% of patients ultimately require liver transplantation for conditions including intractable pruritus and progressive liver dysfunction. Supportive care, transplant preparation, and post-transplant management continue to address advanced disease needs and reinforce the role of multidisciplinary centers.
Ileal bile acid transporter inhibitors accounted for 38.55% of the Alagille syndrome treatment market size within the drug class and active ingredient segment in 2025. This position reflected orphan pricing, recent approvals, and the lack of another high-value targeted agent described in the supplied research. Maralixibat and odevixibat remained the principal medicines in this class, with differences in approved age range, formulation, and distribution arrangements influencing prescribing decisions.
Maralixibat is forecast to grow at a CAGR of 10.80% from 2026 to 2031. Its growth is linked to approvals across more than 40 countries, the June 2025 tablet launch, and completed enrollment of the Phase 3 EXPAND study in March 2026. Topline data are expected in the fourth quarter of 2026, and the study could support a label extension to biliary atresia, while supportive therapies remain relevant where IBAT inhibitors are not reimbursed.
Complete Report Scope:
- By Treatment Modality
- Pharmacological Therapy
- Surgical Intervention
- Supportive and Nutritional Care
- Liver-Transplant Preparation and Post-Transplant Care
- By Drug Class and Active Ingredient
- Ileal Bile Acid Transporter Inhibitors
- Maralixibat
- Odevixibat
- Ursodeoxycholic Acid
- Bile Acid Sequestrants
- Cholestyramine
- Colesevelam
- Rifampicin
- Naltrexone
- Sertraline
- Fat-Soluble Vitamin Formulations
- Other Supportive Medicines
- By Route of Administration
- Oral
- Injectable and Parenteral Therapy
- Other Routes of Administration
- By Patient Age Group
- Infants Younger Than 12 Months
- Children Aged 1 to 11 Years
- Adolescents Aged 12 to 17 Years
- Adults Aged 18 Years and Older
- By End User
- Pediatric Hepatology Centers
- Specialty Rare-Disease Clinics
- Tertiary Hospitals
- Liver-Transplant Centers
- Specialty Genetic Clinics
- Home-Based Treatment and Monitoring
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 38.67% of the Alagille syndrome treatment market share in 2025, making it the largest regional segment. U.S. orphan drug designations and the Breakthrough Therapy Designation for maralixibat supported earlier use than in many other countries. Mirum reported U.S. LIVMARLI net product sales of USD 244.7 million in 2025, up 69% year over year.Canada expanded its treatment setting during 2025 after odevixibat approval and the conclusion of maralixibat reimbursement negotiations, while Mexico’s less developed rare-disease insurance framework limited near-term use outside urban tertiary centers. Europe is the second-largest geography in the supplied research, with Germany, the United Kingdom, and France forming the main country markets. The 2025 European authorization of LIVMARLI tablets and the 2024 conditional approval of odevixibat created a two-IBAT-inhibitor setting, although national assessment processes differ across countries and can create uneven access.
Asia-Pacific is forecast to grow at a 9.58% CAGR from 2026 to 2031, the fastest regional rate in the supplied estimates. The region is a key growth area for the Alagille syndrome treatment market. Japan approved maralixibat in March 2025, and China expanded its label to patients aged 3 months and older in May 2024. CANbridge and Baheal Medical formed a partnership in August 2025 covering mainland China, Hong Kong, and Macau, while Australia’s PBAC completed an odevixibat review in March 2026.
List of Companies Covered in this Report:
- Abbvie
- Alfasigma S.p.A.
- CANbridge Pharmaceuticals, Inc.
- Digestive Care, Inc.
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Ipsen
- Laboratoires CTRS
- Leadiant Biosciences, Inc.
- Mirum Pharmaceuticals, Inc.
- Novartis
- Pfizer
- Sanofi
- Strides Pharma Science
- Takeda Pharmaceuticals
- Teva Pharmaceutical Industries
- Zydus Lifesciences Limited
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alfasigma S.p.A.
- CANbridge Pharmaceuticals, Inc.
- Digestive Care, Inc.
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Limited
- Ipsen Pharma
- Laboratoires CTRS
- Leadiant Biosciences, Inc.
- Mirum Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Strides Pharma Science Limited
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Zydus Lifesciences Limited
